|05/28/15||Synta Announces Presentations at the 2015 ASCO Annual Meeting|
|Feasibility of Ganetespib Combination Therapy Demonstrated in
Three Investigator-Sponsored Trials
STA-12-8666 Results in Pediatric Sarcoma Models Highlighted in
Poster Discussion Session
LEXINGTON, Mass.--(BUSINESS WIRE)--May 28, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Phase 1
clinical results from three investigator-sponsored trials evaluating
ganetespib combination therapy in ALK-positive lung cancer,
|05/27/15||Synta to Present at the Jefferies 2015 Global Healthcare Conference|
|LEXINGTON, Mass.--(BUSINESS WIRE)--May 27, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company will present at the Jefferies 2015 Global Healthcare Conference
on Wednesday, June 3, at 11:30 a.m. (ET) in New York.
A live webcast
and replay of the presentation will be available on the "Investors"
section of the Company's website, www.syntapharma.com.
About Synta Pharmaceuticals
Synta Phar... |
|05/07/15||Synta Reports First Quarter 2015 Financial Results|
|- Webcast and Conference Call Today, May 7, at 10:00 AM ET -
LEXINGTON, Mass.--(BUSINESS WIRE)--May 7, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial
results for the first quarter ended March 31, 2015 and provided an
“We remain encouraged by the progress of our ganetespib clinical program
including enrollment in our pivotal, Phase 3 GALAXY-2 trial in non-small
cell lung adenocarcinoma, an... |
|04/30/15||Synta to Host Conference Call and Webcast of First Quarter 2015 Financial Results on May 7, 2015|
|LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 30, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will
report its first quarter 2015 financial results on Thursday, May 7,
2015, before market open.
Following the announcement, management will host a conference call and
webcast at 10:00 a.m. ET that morning to discuss the first quarter
results and provide operational updates.
The conference call can be accessed by ... |